Detection rate of depression symptoms and its influencing factors in breast cancer patients during chemotherapy in China: a meta-analysis and systematic review / 中华健康管理学杂志

ABSTRACT

Objective:To systematically evaluate the prevalence of depressive symptoms and its influencing factors in breast cancer patients during chemotherapy in China.Methods:The databases such as CNKI, Wanfang Data, VIP, PubMed, Web of Science and Embase were searched with retrieval terms of breast cancer, breast tumor, chemotherapy, depressive symptom, mental health, melancholia, Chinese, etc for the literature related to the prevalence of depressive symptoms in breast cancer patients during chemotherapy in China. Relevant literature from the establishment of the databases to August 2022 were retrieved. Two researchers screened the literature independently, extracted data and evaluated the risk of bias in the included studies, and prevalence of depressive symptoms and its influencing factors in breast cancer patients during chemotherapy in China were systematically evaluated by using RevMan 5.3 and Stata 14.1 software.Results:A total of 18 studies were included, including 2 678 subjects. Meta-analysis results showed that the prevalence of depressive symptom in breast cancer patients in China was 51.60% (95% CI 44.10%-55.10%). The results of subgroup analysis showed that age ( OR=2.55, 95% CI 1.26-5.14), educational level ( OR=2.01, 95% CI 1.01-3.98), marital status ( OR=0.50, 95% CI 0.29-0.86), occupational status ( OR=3.29, 95% CI 1.04-10.46), clinical staging ( OR=0.32, 95% CI 0.22-0.46) and frequency of chemotherapy ( OR=0.39, 95% CI 0.17-0.86) were the influencing factors of depressive symptoms in breast cancer patients during chemotherapy in China (all P<0.05). Conclusions:The prevalence of depressive symptoms in breast cancer patients during chemotherapy in China is high. Breast cancer patients undergoing chemotherapy who are under 50 years old, having a high school education or lower, are not married, currently employed, and in clinical stage 3-4 and receiving more than 4 chemotherapy cycles are more likely to experience depressive symptoms.